Akinsanya Karen 4
4 · Nautilus Biotechnology, Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
NAUT Director Karen Akinsanya Receives 45,000-Share Option Award
What Happened
Karen Akinsanya, a director of Nautilus Biotechnology, was granted a derivative award on 2026-06-18 covering 45,000 shares. The grant is reported as acquired at $0.00 (no cash paid at grant) and is recorded as a derivative (an option) rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed within the standard reporting window).
- Transaction code: A (Grant/Award); Instrument: derivative option covering 45,000 shares; reported acquisition price: $0.00.
- Vesting: Per footnote, subject to continued service as a “Service Provider,” one‑twelfth of the option vests monthly after the grant date (i.e., monthly vesting over 12 months).
- Shares owned after transaction: not specified in the provided filing.
- No indication this was a cash purchase or an immediate sale; this is a compensation award.
Context
This is an option award that will convert to vested rights over time if the insider remains a service provider; it does not represent immediately tradable shares until vesting (and possible exercise/settlement) occurs. Awards to directors are commonly part of compensation packages and do not, by themselves, signal buying or selling intent.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-18+45,000→ 45,000 totalExercise: $2.28Exp: 2036-06-18→ Common Stock (45,000 underlying)
Footnotes (1)
- [F1]Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).